Novo Nordisk A/S B

Novo-Nordisk is a global healthcare company engaged in the innovation of diabetes care. Co. also provides haemophilia care, growth hormone therapy and hormone replacement therapy. The Diabetes care business segment includes research, development, manufacturing and marketing of products within the areas of insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD) and obesity. The Biopharmaceuticals business segment includes research, development, manufacturing and marketing of products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas.
  • TickerNOVO B
  • ISINDK0060534915
  • ExchangeNasdaq Nordic Copenhagen
  • SectorPharmaceuticals & Biotechnology
  • CountryDenmark

Analysts

Ole-Andreas Krohn ...
  • Rune Majlund Dahl

Northern Lights

Rune Majlund Dahl

Novo Nordisk (Buy, TP: DKK410.00) - Another CV win for Novo Nordisk

Eli Lilly presented the detailed results from the REWIND study with Trulicity at ADA, showing superiority (12% reduction) to placebo (Ozempic 26%), adding another CV win for Novo Nordisk. Eli Lilly also showed the side-effect profile needs to improve for tirzepatide, while efficacy looks strong. Novo Nordisk focused on oral semaglutide, creating awareness before a likely launch. We maintain our BUY and DKK410 target price.

Antoine Boivin-Champeaux ...
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Pierre Corby
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 06/11/2019

...

Antoine Boivin-Champeaux ...
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Pierre Corby
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 11/06/2019

...

Martial Descoutures ...
  • Pierre Corby

Novo Nordisk : Few changes to expect after ADA

>Confirmations for Novo Nordisk - After the filing of oral Semaglutide at end-Q1 2019 in the US and early Q2 2019 in Europe, we did not expect any specific announcements from Novo Nordisk at the ADA (American Diabetes Association) congress. This congress was rather an opportunity to review the results of oral semaglutide and confirm its potential in the class. However, Novo presented additional results on the PIONEER 2 study, oral sema vs empagliflozin (SGLT2) and PI...

Rune Majlund Dahl

Novo Nordisk (Buy, TP: DKK410.00) - Another CV win for Novo Nordisk

Eli Lilly presented the detailed results from the REWIND study with Trulicity at ADA, showing superiority (12% reduction) to placebo (Ozempic 26%), adding another CV win for Novo Nordisk. Eli Lilly also showed the side-effect profile needs to improve for tirzepatide, while efficacy looks strong. Novo Nordisk focused on oral semaglutide, creating awareness before a likely launch. We maintain our BUY and DKK410 target price.

Martial Descoutures ...
  • Pierre Corby

Novo Nordisk : Few changes to expect after ADA

>Confirmations for Novo Nordisk - After the filing of oral Semaglutide at end-Q1 2019 in the US and early Q2 2019 in Europe, we did not expect any specific announcements from Novo Nordisk at the ADA (American Diabetes Association) congress. This congress was rather an opportunity to review the results of oral semaglutide and confirm its potential in the class. However, Novo presented additional results on the PIONEER 2 study, oral sema vs empagliflozin (SGLT2) and PI...

Martial Descoutures ...
  • Pierre Corby

Novo Nordisk : Peu de modifications à attendre post ADA

>Des confirmations pour Novo Nordisk - Après le dépôt d’enregistrement de semaglutide oral fin du T1 aux US et début du T2 en Europe, nous ne nous attendions pas à des annonces spécifiques de la part de Novo Nordisk lors du congrès de l’ADA. Ce congrès a été plutôt l’occasion de revenir sur les résultats de semaglutide oral et de confirmer son potentiel dans la classe. Novo Nordisk a présenté cependant des résultats complémentaires sur l’étude PIONEER 2, sema oral vs ...

Rune Majlund Dahl

Novo Nordisk (Buy, TP: DKK410.00) - Another ADA with CV focus

We will attend this year’s ADA conference in San Francisco (7–11 June), where we expect focus yet again to be on cardiovascular (CV) benefits. We expect detailed results from the REWIND study with Trulicity (Eli Lilly), but we do not believe Trulicity will beat the c26% CV reduction seen with semaglutide. We also expect focus on oral semaglutide, and Eli Lilly’s titration study with the GIP/GLP-1 analogue tirzepatide. We reiterate our BUY and DKK410 target price.

Ole-Andreas Krohn ...
  • Rune Majlund Dahl

Northern Lights

Antoine Boivin-Champeaux ...
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Pierre Corby
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 06/11/2019

...

Antoine Boivin-Champeaux ...
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Pierre Corby
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 11/06/2019

...

Jørgen Lian ...
  • Nicolay Dyvik
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

ResearchPool Subscriptions

Get the most out of your insights

Get in touch